Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Stoke Therapeutics, Inc. (STOK)

Stoke Therapeutics Q3 net loss widens to $73.6 million, or $1.08 per share

Mixed Impact 3 of 5 earnings Written later

Stoke Therapeutics reported third-quarter 2026 results, with revenue of $11.3 million, up from $10.6 million a year earlier, while its net loss widened to $73.6 million from $38.3 million as research and development and sales, general and administrative spending rose. The company said its $358.8 million in cash, cash equivalents and marketable securities is expected to fund operations into early 2028, and it still anticipates the Phase 3 EMPEROR data readout in the third quarter of 2027.

Key points

  • Q3 2026 revenue was $11.3 million, compared with $10.6 million in Q3 2025.
  • Q3 2026 net loss was $73.6 million, or $1.08 per share, versus $38.3 million, or $0.65 per share, a year earlier.
  • Research and development expenses rose to $59.8 million from $37.7 million, driven by zorevunersen advancement.
  • Cash, cash equivalents and marketable securities were $358.8 million as of September 30, 2026.

The filing

CompanyStoke Therapeutics, Inc. (STOK)
Form8-K, current report
Filed with the SECOct 29, 2026, 4:05 PM ET
Accession number0001193125-26-437775

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 29, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.